title: Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin.
authors.affiliation: Merck Gesellschaft mbH, Vienna, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Marhardt
authors.affiliation: EMD Serono, Rockland/MA, USA.
authors.forename: N
authors.initials: N
authors.lastname: Muurahainen
mesh_terms: D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D005346:Fibroblast Growth Factors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology
chemical_list: D018501:Antirheumatic Agents; C113569:fibroblast growth factor 18; D005346:Fibroblast Growth Factors